Endo International

ENDP-Q

Analysis and Opinions about ENDP-Q

Signal
Opinion
Expert
BUY
BUY
October 15, 2019
Likes it. This space is getting crucified. They recently settled a big lawsuit. It will earn $2.17/share in 2019 and $2.30/share in 2020. It trades at 1.5x earnings--very cheap. He has a trading position in ENDP.
Show full opinionHide full opinion
Likes it. This space is getting crucified. They recently settled a big lawsuit. It will earn $2.17/share in 2019 and $2.30/share in 2020. It trades at 1.5x earnings--very cheap. He has a trading position in ENDP.
DON'T BUY
DON'T BUY
July 29, 2019

A pharma with two-thirds of sales from generics. They're wrapped up in an opiod trial (that mostly involves JNJ). The stock has fallen off and if there is a negative judgement, Endo will get hit though JNJ will bear the brunt.

Show full opinionHide full opinion

A pharma with two-thirds of sales from generics. They're wrapped up in an opiod trial (that mostly involves JNJ). The stock has fallen off and if there is a negative judgement, Endo will get hit though JNJ will bear the brunt.

BUY WEAKNESS
BUY WEAKNESS
April 22, 2019
He's recommend this before and owns a lot of it. It reports earnings on May 9 and likely nothing will happen till then. Buy at $6-7. The stock fell last year, because all the generic drug-makers are vulnerable to lawsuits from American states during the opioid crisis. Endo has a pill more powerful than oxy contin Expects good earnings.
Show full opinionHide full opinion
He's recommend this before and owns a lot of it. It reports earnings on May 9 and likely nothing will happen till then. Buy at $6-7. The stock fell last year, because all the generic drug-makers are vulnerable to lawsuits from American states during the opioid crisis. Endo has a pill more powerful than oxy contin Expects good earnings.
BUY
BUY
July 17, 2018

His model price is $44.72, which is a 300% upside. This stock is very high risk but it has been rising recently as he predicted it would. This stock, like Teva and Bausch Health, were part of the most undervalued sector of the market 9 months ago, have been rising, and probably have more to go.

Show full opinionHide full opinion

His model price is $44.72, which is a 300% upside. This stock is very high risk but it has been rising recently as he predicted it would. This stock, like Teva and Bausch Health, were part of the most undervalued sector of the market 9 months ago, have been rising, and probably have more to go.

PAST TOP PICK
PAST TOP PICK
March 14, 2018

(A Top Pick June 2/17 Down 45%.) He sees this is being dragged down by the generic drug selloff. When it was removed from the S&P500 index it was impacted negatively. It is also embroiled in the opioid crisis in the US. He likes the multiples and sees a model price of $24 – a potential 250% upside. He will buy more.

Show full opinionHide full opinion

(A Top Pick June 2/17 Down 45%.) He sees this is being dragged down by the generic drug selloff. When it was removed from the S&P500 index it was impacted negatively. It is also embroiled in the opioid crisis in the US. He likes the multiples and sees a model price of $24 – a potential 250% upside. He will buy more.

TOP PICK
TOP PICK
June 2, 2017

Moved their head office to Ireland, so it got kicked out of the S&P 500. The stock price has fallen from almost $100 to $13.57. His model price is $32.84, a 140% upside. (Analysts’ price target is $15.50.)

Show full opinionHide full opinion

Moved their head office to Ireland, so it got kicked out of the S&P 500. The stock price has fallen from almost $100 to $13.57. His model price is $32.84, a 140% upside. (Analysts’ price target is $15.50.)

COMMENT
COMMENT
January 17, 2017

This is for the risk-takers. The stock was close to $70 a share within the last 18 months. Now it is around $13. The concern is that their business model has gone broke. They decided they wanted to acquire companies instead of spending a lot of money in the lab in R&D and not generating anything. They just reaffirmed guidance, and they should earn $4-$4.50. On a $13 stock, if they just earned half of that, it is one of your cheapest companies in the whole healthcare space. If we just get some stability in the outlook and know what is going to replace Obama care, this stock could easily double over the next 5 years.

Show full opinionHide full opinion

This is for the risk-takers. The stock was close to $70 a share within the last 18 months. Now it is around $13. The concern is that their business model has gone broke. They decided they wanted to acquire companies instead of spending a lot of money in the lab in R&D and not generating anything. They just reaffirmed guidance, and they should earn $4-$4.50. On a $13 stock, if they just earned half of that, it is one of your cheapest companies in the whole healthcare space. If we just get some stability in the outlook and know what is going to replace Obama care, this stock could easily double over the next 5 years.

Showing 1 to 7 of 7 entries
  • «
  • 1
  • »

Endo International(ENDP-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 2

Stockchase rating for Endo International is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Endo International(ENDP-Q) Frequently Asked Questions

What is Endo International stock symbol?

Endo International is a American stock, trading under the symbol ENDP-Q on the NASDAQ (ENDP). It is usually referred to as NASDAQ:ENDP or ENDP-Q

Is Endo International a buy or a sell?

In the last year, 2 stock analyst published opinions about ENDP-Q. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Endo International.

Is Endo International a good investment or a top pick?

Endo International was recommended as a Top Pick by Brian Acker, CA on 2019-10-15. Read the latest stock experts ratings for Endo International.

Why is Endo International stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Endo International worth watching?

2 stock analyst on Stockchase covered Endo International In the last year. It is a trending stock that is worth watching.

What is Endo International stock price?

On 2020-06-04, Endo International (ENDP-Q) stock closed at a price of $3.98.